• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂改善了重症新型冠状病毒肺炎合并高血压患者的预后。
Sci China Life Sci. 2021 May;64(5):836-839. doi: 10.1007/s11427-020-1813-0. Epub 2020 Sep 21.
2
COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.2019冠状病毒病、高血压与肾素-血管紧张素-醛固酮系统阻滞剂：BRACE-CORONA试验
Cardiovasc Res. 2020 Dec 1;116(14):e198-e199. doi: 10.1093/cvr/cvaa325.
3
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
4
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.2019冠状病毒病与高血压：血管紧张素转换酶2及肾素-血管紧张素系统的作用
Adv Chronic Kidney Dis. 2020 Sep;27(5):404-411. doi: 10.1053/j.ackd.2020.07.002. Epub 2020 Jul 4.
5
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。
Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.
6
The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.在新冠肺炎患者中使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的争议。
J Renin Angiotensin Aldosterone Syst. 2021 Jan-Dec;22(1):1470320320987118. doi: 10.1177/1470320320987118.
7
COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome.高血压患者感染新型冠状病毒肺炎（COVID-19）病情更严重；血管紧张素转换酶抑制剂（ACEI）/血管紧张素Ⅱ受体阻滞剂（ARB）治疗不影响临床严重程度及预后。
J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.056. Epub 2020 May 28.
8
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体阻滞剂对 COVID-19 合并高血压患者的影响（COVIDECA 研究）。
Am J Cardiol. 2021 May 15;147:58-60. doi: 10.1016/j.amjcard.2021.02.009. Epub 2021 Feb 20.
9
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.中国 2 家中心回顾性研究：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在高血压合并 COVID-19 患者中的持续使用效果。
Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651.
10
Angiotensin-converting enzyme 2 as a versatile player in the management of coronavirus disease 2019.血管紧张素转换酶2在2019冠状病毒病管理中的多面角色
J Diabetes Investig. 2020 Sep;11(5):1120-1122. doi: 10.1111/jdi.13346. Epub 2020 Aug 25.

引用本文的文献

1
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.重症 COVID-19 患者的生物标志物与早发性急性肾损伤：一项前瞻性单中心观察性研究
BMC Nephrol. 2025 Jul 1;26(1):294. doi: 10.1186/s12882-025-04267-0.
2
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.系统评价和荟萃分析 ACEI/ARB 在东亚 COVID-19 患者中的临床结局。
PLoS One. 2023 Jan 12;18(1):e0280280. doi: 10.1371/journal.pone.0280280. eCollection 2023.
3
Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19：系统评价和荟萃分析揭示了大量观察性研究中的关键偏倚。
J Am Heart Assoc. 2022 Jun 7;11(11):e025289. doi: 10.1161/JAHA.122.025289. Epub 2022 May 27.
4
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.高血压COVID-19患者长期使用肾素-血管紧张素-醛固酮抑制剂：一项西班牙登记研究和荟萃分析的结果
Med Clin (Engl Ed). 2022 Apr 8;158(7):315-323. doi: 10.1016/j.medcle.2021.04.026. Epub 2022 May 3.
5
The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review.不同类别抗高血压药物对新冠肺炎合并高血压患者的影响：一篇综述
Int J Hypertens. 2022 Jan 21;2022:5937802. doi: 10.1155/2022/5937802. eCollection 2022.
6
Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium.探讨 ACEIs/ARBs 使用与 COVID-19 预后的关系：来自比利时全国医院监测数据的多状态建模研究。
BMJ Open. 2021 Sep 16;11(9):e053393. doi: 10.1136/bmjopen-2021-053393.
7
Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂在一级预防和新型冠状病毒肺炎中的应用
J Am Heart Assoc. 2021 Aug 3;10(15):e021154. doi: 10.1161/JAHA.120.021154. Epub 2021 Jul 29.
8
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.慢性使用肾素-血管紧张素-醛固酮抑制剂治疗高血压合并 COVID-19 患者：来自西班牙登记和荟萃分析的结果。
Med Clin (Barc). 2022 Apr 8;158(7):315-323. doi: 10.1016/j.medcli.2021.04.005. Epub 2021 May 6.
9
The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.免疫系统、肾素-血管紧张素-醛固酮系统（RAAS）与 RAAS 抑制剂之间的相互作用可能会调节 COVID-19 的转归：系统评价。
J Clin Pharmacol. 2021 Aug;61(8):987-1000. doi: 10.1002/jcph.1852. Epub 2021 Apr 7.
10
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.血管紧张素转换酶 2（ACE2）药理学调控的综合指南，该酶是 SARS-CoV-2 的进入受体。
Pharmacol Ther. 2021 May;221:107750. doi: 10.1016/j.pharmthera.2020.107750. Epub 2020 Dec 1.

本文引用的文献

1
[Angiotension converting enzyme 2 in the context of 2019 novel coronavirus infection：friend or foe？].2019新型冠状病毒感染中的血管紧张素转换酶2：朋友还是敌人？
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):527-531. doi: 10.3760/cma.j.cn112148-20200303-00149.
2
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
3
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools.理解 SARS-CoV-2 介导的炎症反应：从机制到潜在的治疗工具。
Virol Sin. 2020 Jun;35(3):266-271. doi: 10.1007/s12250-020-00207-4. Epub 2020 Mar 3.
4
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
5
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.从 2019 年新冠病毒感染患者中提取的临床和生化指标与病毒载量和肺部损伤有关。
Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8. Epub 2020 Feb 9.
6
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
7
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.血管紧张素转换酶 2 和血管紧张素 1-7：新的治疗靶点。
Nat Rev Cardiol. 2014 Jul;11(7):413-26. doi: 10.1038/nrcardio.2014.59. Epub 2014 Apr 29.
10
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.联合肾素-血管紧张素系统阻断和血管紧张素转换酶 2 治疗实验性心肌梗死：对未来治疗方向的启示。
Clin Sci (Lond). 2012 Dec;123(11):649-58. doi: 10.1042/CS20120162.

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension.

作者信息

Meng Xiao, Liu Ya, Wei Chenchen, Zhang Kai, Zhang Yi, Zhong Ming, Zhang Cheng, Zhang Yun

机构信息

The Key Laboratory of Cardiovascular Remodeling and Function Research, Ministry of Education of China, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.

Department of Infectious Disease, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

出版信息

Sci China Life Sci. 2021 May;64(5):836-839. doi: 10.1007/s11427-020-1813-0. Epub 2020 Sep 21.

DOI:10.1007/s11427-020-1813-0
PMID:32975722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7518094/
Abstract
摘要